日韩精品欧美专区,国产v综合v亚洲欧美久久,jizz性欧美2,国产精品色婷婷

Ask the Experts: Polio

Results (17)

Since the Global Polio Eradication Initiative was launched in 1988, the number of polio cases worldwide has declined by more than 99.99%. Among the three wild poliovirus (WPV) serotypes, only type 1 (WPV1) has been detected since 2012. Global eradication of type 2 WPV was declared in 2015; type 3 WPV was declared eradicated in 2019. The number of detected WPV1 cases has reached a historic low (33 cases in 2018 and 176 in 2019) in the last two countries with endemic WPV1 transmission (Afghanistan and Pakistan). However, during 2021–2022, Malawi and Mozambique reported nine WPV1 cases that were genetically linked to Pakistan. These cases highlight the risk for importation and the importance of maintaining enhanced global monitoring and surveillance.

This decline in polio cases worldwide is attributable primarily to use of the live, attenuated oral poliovirus vaccine (OPV) in national routine immunization schedules and mass vaccination campaigns. The success and safety record of OPV use is offset by the rare emergence of genetically divergent vaccine-derived polioviruses (VDPVs), whose genetic drift from the parental OPV strains indicates prolonged replication or circulation. Circulating VDPVs (cVDPVs) can emerge in areas with low immunization coverage and can cause outbreaks of paralytic polio. In addition, immunodeficiency-associated VDPVs (iVDPVs) can emerge in people with primary immunodeficiencies and can replicate and be excreted for years. During January 2020–April 2022, a total of 1,856 cVDPV cases were identified in 33 countries. In July 2022, a case of paralytic polio caused by vaccine-derived poliovirus type 2 (VDPV2) was confirmed in an unvaccinated young adult from Rockland County, New York.

In April 2016, all OPV-using countries switched from using trivalent OPV (tOPV; Sabin types 1, 2, and 3) to bivalent OPV (bOPV; Sabin types 1 and 3). To control and prevent cVDPV2 outbreaks, traditional monovalent type 2 OPV (mOPV2) has been distributed in affected countries; in addition, a novel monovalent type 2 OPV (nOPV2) that is less likely to produce cVPDV disease was listed under an Emergency Use Authorization (EUL) by the World Health Organization (WHO) in November 2020, (Bio Farma, Indonesia) to address the rising cases of cVDPV2. As of March 2023, close to 600 million doses of the?nOPV2?have been used across 28 countries in outbreak response.

Additional information about the polio eradication program is available on the CDC website at?www.cdc.gov/polio.

Last reviewed: July 23, 2023

In the U.S., all infants and children should receive 4 doses of IPV at ages 2, 4, 6–18 months, and 4–6 years. The first dose may be given as early as 6 weeks of age. The final dose should be administered at 4 years of age or older, regardless of the number of previous doses, and should be given 6 months or more after the previous dose. A fourth dose in the routine IPV series is not necessary if the third dose was given at 4 years of age or older and 6 months or more after the previous dose.

Infants and children traveling to areas where there has been wild or vaccine-derived poliovirus (cVDPV) circulation in the last 12 months should be vaccinated according to the routine schedule. If the routine series cannot be administered within the recommended intervals before protection is needed, an accelerated schedule can be used: 1) the first dose should be given to infants 6 weeks of age and older, 2) the second and third doses should be administered at 4 weeks or more after the previous doses, and 3) the minimum interval between the third and fourth doses is 6 months. If the age-appropriate series is not completed before departure, the remaining IPV doses to complete a full series should be administered when feasible, at the intervals recommended for the accelerated schedule. If doses are needed while residing in the affected country, the polio vaccine that is available (IPV or oral polio vaccine [OPV]) may be administered.

In addition to single-antigen IPV, five pediatric combination vaccines that contain IPV vaccine are licensed and recommended for use in the United States: DTaP-HepB-IPV (Pediarix, GSK), DTaP-IPV/Hib (Pentacel, Sanofi), DTaP-IPV (Kinrix, GSK), DTaP-IPV (Quadracel, Sanofi), and DTaP-IPV-Hib-HepB (Vaxelis, MSP Vaccine Company).

Last reviewed: July 23, 2023

The schedule for polio vaccination for unvaccinated or under-vaccinated older children and adults is 2 doses of IPV separated by 4–8 weeks, and a third dose 6–12 months after the second dose (the final dose must be given after the fourth birthday). If an accelerated schedule is needed, the first two doses should be separated by at least 4 weeks and the third (final) dose given at least 6 months after the second dose. In June 2023, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended that any adult known or suspected to be unvaccinated or incompletely vaccinated should complete a primary IPV series.

Last reviewed: July 23, 2023


0:59

View All Video Questions

Last reviewed: May 23, 2023

Most adults residing in the United States are presumed to be protected against polio because they received routine childhood immunization and have only a small risk of exposure to poliovirus in the United States. For decades, routine polio vaccination of U.S. residents 18 years of age and older, including those working in healthcare or in healthcare-related training, was not recommended.

In June 2022, a case of paralytic polio caused by vaccine-derived poliovirus type 2 (VDPV2) was confirmed in an unvaccinated young adult from Rockland County, New York, and wastewater surveillance in the region repeatedly detected evidence of poliovirus over the following months, suggesting the presence of an unknown number of asymptomatically infected people in the community. People who are fully vaccinated with IPV are protected from polio illness but may shed virus in their feces, if exposed. This experience underscored the ongoing risk, however small, of paralytic polio among incompletely vaccinated people in the United States.

CDC’s ACIP recommended in June 2023, that all adults (18 years and older) who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary 3-dose vaccination series with IPV: 2 doses of IPV administered at an interval of 4–8 weeks; and a third dose 6–12 months after the second. If an adult previously received only one or two documented doses of polio vaccine (either trivalent OPV or IPV), the person should receive the remaining dose(s) of IPV necessary to complete the series, regardless of the interval since the last dose. It is not necessary to restart the vaccination series.

Polio vaccination with a complete primary series is recommended for all travelers to countries with wild poliovirus (WPV) or vaccine-derived poliovirus (VDPV) circulation. WHO recommends that countries affected by WPV or cVDPV require long-term visitors (4 weeks or longer) to provide proof of polio vaccination before leaving the country. For additional information on countries with WPV or VDPV circulation, as well as country-specific requirements for documentation of vaccination, consult the CDC Travelers’ Health website (wwwnc.cdc.gov/travel/).

Adults who have completed a routine series of polio vaccine (with trivalent OPV or IPV in any combination) are considered to have lifelong immunity to poliomyelitis, but data on duration of immunity are lacking. In June 2023, ACIP affirmed and clarified its longstanding recommendation that certain adults at increased risk of exposure to poliovirus may receive a single lifetime adult booster dose of IPV. Adults in situations that put them at increased risk of poliovirus exposure include: travelers going to countries where polio is epidemic or endemic; laboratory and healthcare workers who handle specimens that might contain polioviruses; and, healthcare workers or other caregivers who have close contact with a person who could be infected with poliovirus.

Last reviewed: July 23, 2023

Immunity to one of the serotypes of polio does not produce significant immunity to the other serotypes. A history of having recovered from polio disease should not be considered evidence of immunity to polio. You should complete a primary series of IPV if he is known or suspected to have been unvaccinated or incompletely vaccinated against polio. If he received a primary series in childhood, a single adult booster dose may be given before travel to an area where polio vaccination is recommended.

Last reviewed: July 23, 2023

In June 2023, ACIP recommended that all adults (18 years and older) in the United States who are known or suspected to be unvaccinated or incompletely vaccinated against polio should complete a primary 3-dose vaccination series with IPV: 2 doses of IPV administered at an interval of 4–8 weeks; and a third dose should be administered 6–12 months after the second. Previously, ACIP did not recommend IPV vaccination of unvaccinated or incompletely vaccinated adults who lacked a specific increased risk for exposure to polio (e.g., due to travel). Most U.S. adults may be presumed to be vaccinated against polio unless there is a specific reason to believe otherwise (e.g., an adult whose parents were known to have refused vaccinations). Rates of polio vaccination among children in the United States have been extremely high for decades.

Last reviewed: July 23, 2023


2:23

View All Video Questions

Last reviewed: December 6, 2023

In June 2023, ACIP affirmed its longstanding recommendation that adults who received a primary series of trivalent OPV (tOPV) or IPV in any combination and who are at increased risk of poliovirus exposure may receive another dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose with IPV for adults.

The following are examples of vaccinated adults at increased risk of exposure who may receive a single lifetime booster dose of IPV:

  • Travelers who are going to countries where polio is epidemic or endemic (see polio information for travelers at wwwnc.cdc.gov/travel/)
  • Laboratory and healthcare workers who handle specimens that might contain polioviruses
  • Healthcare workers or other caregivers who have close contact with a person who could be infected with poliovirus
Last reviewed: July 23, 2023

CDC recommends that all travelers to countries affected by wild (WPV) or circulating vaccine-derived poliovirus (cVDPV) be vaccinated fully against polio. Adults who were fully vaccinated during childhood may receive an additional (single) lifetime booster dose of polio vaccine.

WHO recommends that countries affected by wild poliovirus or cVDPV outbreaks require residents and long-term (4 weeks or more) visitors show proof of polio vaccination before leaving the country. These recommendations are regularly reviewed and updated. Visit CDC’s Travelers’ Health site for current details about country-specific requirements (wwwnc.cdc.gov/travel/).

Last reviewed: July 23, 2023

It is common practice in many developing countries to administer oral polio vaccine (OPV) to children during both routine visits and periodic vaccination campaigns, so a child’s record may indicate more than 4 doses. Some of these doses may not be valid according to the U.S. immunization schedule.

Doses are considered valid if written documentation indicates that doses of polio vaccine were given after 6 weeks of age and the vaccine received was listed as IPV or trivalent OPV (tOPV). A record simply indicating “OPV” also is acceptable if the OPV was administered before April 1, 2016, and it was not noted as being administered during a vaccination campaign.

There specific criteria for OPV documentation because only trivalent polio vaccine doses count as valid for the U.S. polio vaccination schedule. Trivalent OPV ceased to be used globally in April 2016. OPV administered before April 1, 2016, generally was tOPV. However, “OPV” doses recorded as given during a mass vaccination campaign before April 2016 do not count as valid because such campaigns may have used monovalent or bivalent OPV.

If the history is of a complete series of IPV or tOPV in any combination, at least one dose should be administered on or after 4 years of age and at least 6 months after the previous dose. If a complete series cannot be identified that meets these criteria, then the child should receive as many doses of IPV as needed to complete the U.S. recommended schedule.

Last reviewed: July 23, 2023

Use the date of administration to make a presumptive determination of what type of OPV was received. Only trivalent doses count as valid for the U.S. polio vaccination schedule.

Trivalent OPV was used throughout the world before April 2016. In April 2016, all countries using tOPV switched to bivalent OPV (bOPV). In addition, some countries also use monovalent OPV (mOPV) during special vaccination campaigns. Doses recorded as bOPV or mOPV, and unspecified OPV doses noted on an immunization record as given during a vaccination campaign, do not count as valid doses for the U.S. polio vaccination schedule.

You may count a record of an “OPV” dose as valid if the dose was administered before April 1, 2016, and was not noted as being administered as part of a mass vaccination campaign. OPV doses administered on or after April 1, 2016, should not be counted as a valid dose for the U.S. polio vaccination schedule.

Last reviewed: July 23, 2023

CDC published a revised ACIP recommendation for IPV on August 6, 2009, to include a dose given at age 4 through 6 years (and at least 6 months after the preceding dose), regardless of the number of doses given before the fourth birthday. In general, you do not need to administer an additional IPV dose to older teens (or adults) who had already completed a routine 4-dose schedule of polio vaccination before their fourth birthday before the change was published in August 2009; however, if a dose given after the fourth birthday is needed for compliance with state requirements, you may want to check with your state immunization program or immunization registry manager to see what they accept/expect in this case. Contact information for state immunization managers can be found at?www.immunize.org/coordinators.

Last reviewed: July 23, 2023

Polio vaccine given outside the United States is valid if written documentation indicates that all doses were given after 6 weeks of age and the vaccine received was IPV or trivalent OPV (tOPV). Only trivalent polio vaccine counts toward the U.S. schedule. No doses of OPV given since April 1, 2016, count toward the U.S. polio vaccination schedule because, on that date, all countries routinely using tOPV switched to bivalent OPV. Please see other detailed answers concerning details on assessment of OPV doses by the date of administration.

If both tOPV and IPV were or will be administered as part of a series, the total number of doses needed to complete the series is the same as that recommended for the U.S. IPV schedule. If the child is younger than 4 years of age a total of 4 doses of polio vaccine are recommended. If the child is currently 4 years of age or older, a total of 3 doses completes the series. A minimum interval of 4 weeks should separate doses in the series, with the final dose administered on or after the fourth birthday and at least 6 months after the previous dose. If only tOPV was administered, and all doses were given before 4 years of age, 1 dose of IPV should be given at 4 years of age or older, at least 6 months after the last tOPV dose.

Last reviewed: July 23, 2023

People who receive a mixed series of OPV and IPV should receive a total of either 3 or 4 doses depending on the age at the time of the last dose. In this case the recent dose of IPV can be counted as the third and final dose in the series. The minimum interval between the next-to-last and last doses in the polio vaccination series is 6 months and the last dose should be at age 4 years or older.

Last reviewed: July 23, 2023

Yes.

Last reviewed: July 23, 2023

There are no severe reactions known to occur following IPV.

Last reviewed: July 23, 2023

This page was updated on .

日韩精品欧美专区,国产v综合v亚洲欧美久久,jizz性欧美2,国产精品色婷婷
在线观看视频一区二区欧美日韩| 91精品婷婷国产综合久久| 成人精品电影在线观看| 精品国产伦一区二区三区观看方式| 日韩视频在线观看一区二区| 国产精品丝袜久久久久久app| 成人黄色在线网站| 亚洲在线观看免费视频| 国产91在线观看丝袜| 91麻豆视频网站| 久久影院午夜片一区| 一区二区三区不卡视频| 夜色激情一区二区| 成人国产精品免费观看| 91精品国产欧美一区二区18| 日本一区二区不卡视频| 丁香网亚洲国际| 日韩—二三区免费观看av| 日韩精品一区二区三区老鸭窝| 日本免费新一区视频| 91精品在线免费| 日韩电影一区二区三区| 国产精品456| 麻豆视频观看网址久久| 欧美一区二区三区电影| 91免费视频网址| 国产一区二区三区四区五区美女| 成人激情综合网站| 91精品国产综合久久国产大片| 91精品麻豆日日躁夜夜躁| 亚洲国产视频一区| 国产女同互慰高潮91漫画| 欧美一区二区三区啪啪| av动漫一区二区| 欧美一级在线观看| 91蜜桃在线观看| 国产永久精品大片wwwapp| 午夜视频一区在线观看| 欧美性欧美巨大黑白大战| 亚洲精选视频免费看| 狠狠狠色丁香婷婷综合激情| 首页国产欧美日韩丝袜| 老色鬼精品视频在线观看播放| 欧美一区永久视频免费观看| 成人午夜激情影院| 日日夜夜免费精品| 一区二区三区在线视频观看| 久草在线在线精品观看| 国产精品卡一卡二卡三| 欧美日韩一区久久| 69成人精品免费视频| 午夜电影网亚洲视频| 色综合久久久久综合体桃花网| 精品欧美一区二区三区精品久久| voyeur盗摄精品| 久久久久久久久久久久电影| 91丨九色丨蝌蚪富婆spa| 国产精品日日摸夜夜摸av| 国产白丝精品91爽爽久久| 欧美日韩高清一区二区三区| 9人人澡人人爽人人精品| 成a人片国产精品| 午夜成人在线视频| 一本大道久久a久久综合婷婷| 91精品国产日韩91久久久久久| 色欧美片视频在线观看在线视频| 337p亚洲精品色噜噜狠狠| 亚洲色图自拍偷拍美腿丝袜制服诱惑麻豆| 国产精品女人毛片| 成人av电影观看| 国产精品国产三级国产| 国产电影精品久久禁18| 国产精品久久毛片| 亚洲视频每日更新| 日本成人在线网站| 亚洲乱码国产乱码精品精98午夜| 国产精品嫩草久久久久| 香蕉av福利精品导航| 在线亚洲人成电影网站色www| 一级做a爱片久久| 丰满白嫩尤物一区二区| 99久久伊人精品| 91在线视频网址| 国产精品天天摸av网| 日韩国产欧美在线视频| 国产91在线看| 亚洲尤物视频在线| 91免费看`日韩一区二区| 国内精品久久久久影院一蜜桃| 国产日韩综合av| 青草av.久久免费一区| 日本美女视频一区二区| 亚洲一区二区三区视频在线| 国产成人高清在线| 久久久不卡网国产精品二区| 欧美三级日韩三级| 色诱视频网站一区| 日本韩国一区二区三区视频| 欧美日本免费一区二区三区| 日韩欧美中文字幕一区| 欧美午夜精品一区| 欧美一区二区三区在| 国产ts人妖一区二区| 一区二区三区精品久久久| 福利91精品一区二区三区| 日本黄色一区二区| 精品99一区二区| 波多野洁衣一区| 欧美性猛交xxxxxx富婆| 久久精工是国产品牌吗| 色综合久久综合网欧美综合网| 免费成人av在线播放| 欧美一区二区三区视频在线| 国产大陆精品国产| 99精品国产视频| 欧美顶级少妇做爰| 欧美三级蜜桃2在线观看| 久久久精品2019中文字幕之3| 国产一区999| caoporn国产一区二区| 精品美女在线观看| 91蜜桃在线观看| 久久久久久亚洲综合| 国产aⅴ精品一区二区三区色成熟| 最新国产精品久久精品| 26uuu精品一区二区三区四区在线| 午夜电影久久久| 国产欧美日韩麻豆91| 大桥未久av一区二区三区中文| 91在线国产观看| 国产91精品一区二区麻豆网站| 欧美一区二区视频在线观看2022| 午夜精品久久久久久久| 欧美一区二区三区视频| 美女一区二区久久| 椎名由奈av一区二区三区| 中文字幕乱码日本亚洲一区二区| 美日韩一区二区三区| 成人黄色国产精品网站大全在线免费观看| 五月婷婷久久丁香| 亚洲一区二区三区四区在线观看| 中文字幕精品—区二区四季| 国产一区二区三区在线观看精品| 裸体健美xxxx欧美裸体表演| 亚洲国产成人私人影院tom| 午夜精品国产更新| 国产激情偷乱视频一区二区三区| 中文字幕av免费专区久久| 91精品国产欧美一区二区成人| 青青草国产精品97视觉盛宴| 欧美人妇做爰xxxⅹ性高电影| 色屁屁一区二区| 精品久久久久久综合日本欧美| 一区二区三区精品视频| 欧美影院午夜播放| 久久久久99精品国产片| 欧美日韩亚州综合| 欧美精品一区二区三区在线| 亚洲韩国精品一区| 久久午夜色播影院免费高清| 欧美在线综合视频| 欧美日免费三级在线| 亚洲丝袜制服诱惑| 8v天堂国产在线一区二区| 蜜臀av性久久久久蜜臀aⅴ四虎| 亚洲一区在线视频| 成人黄色小视频| 自拍偷拍亚洲激情| 1000部国产精品成人观看| 欧美不卡一二三| 欧美福利电影网| 国产精品久线观看视频| 亚洲一区在线电影| 亚洲欧美日韩国产综合在线| 亚洲夂夂婷婷色拍ww47| av不卡免费在线观看| 4438x成人网最大色成网站| 国产日韩av一区二区| 婷婷国产v国产偷v亚洲高清| 久久精品视频在线免费观看| 久久精品av麻豆的观看方式| 免费人成黄页网站在线一区二区| 亚洲女性喷水在线观看一区| 精品久久一二三区| 欧美美女bb生活片| 国内精品国产成人| 欧美日韩免费视频| 一二三区精品福利视频| 国产精品久久久久婷婷| 日韩av电影免费观看高清完整版在线观看| 亚洲摸摸操操av| 夜夜亚洲天天久久| 麻豆传媒一区二区三区| ...av二区三区久久精品| 美女mm1313爽爽久久久蜜臀| 777欧美精品| 五月天一区二区三区| 国产久卡久卡久卡久卡视频精品| 中文字幕一区二区在线播放| 99久久久精品免费观看国产蜜|